Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases

HPB

Volumn 16, Issue 6, 2014, Pages 550-559

  Van Dam, Ronald M ^a,f   Lodewick, Toine M ^a,b,e,f   Van Den Broek, Maartje A J ^a,f   De Jong, Mechteld C ^a,f   Greve, Jan Willem ^c   Jansen, Rob L H ^a   Bemelmans, Marc H A ^a,f   Neumann, Ulf P ^e,f   Olde Damink, Steven W M ^a,b,d,f   Dejong, Cornelis H C ^a,b,f  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Zuyderland Medical Centre   (Netherlands)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; COLORECTAL LIVER METASTASIS; COMORBIDITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FITNESS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LENGTH OF STAY; LIVER RESECTION; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; TREATMENT INDICATION; TREATMENT OUTCOME; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE COURSE; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; NETHERLANDS; PATHOLOGY; PATIENT SELECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SECONDARY; TIME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COMORBIDITY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NETHERLANDS; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84900839136     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12181     Document Type: Article

References (41)

1. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77: 1254-1262.
2. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH,. (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309-318; discussion 318-21.
3. Altendorf-Hofmann A, Scheele J,. (2003) A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am 12: 165-192.
4. Sharma S, Camci C, Jabbour N,. (2008) Management of hepatic metastasis from colorectal cancers: an update. J Hepatobiliary Pancreat Surg 15: 570-580.
5. Pawlik TM, Abdalla EK, Ellis LM, Vauthey JN, Curley SA,. (2006) Debunking dogma: surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg 10: 240-248.
6. Mehrabi A, Mood ZA, Roshanaei N, Fonouni H, Muller SA, Schmied BM, et al. (2008) Mesohepatectomy as an option for the treatment of central liver tumors. J Am Coll Surg 207: 499-509.
7. Pulitano C, Bodingbauer M, Aldrighetti L, de Jong MC, Castillo F, Schulick RD, et al. (2011) Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol 18: 1380-1388.
8. Fong Y,. (1999) Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 49: 231-255.
9. Pawlik TM, Schulick RD, Choti MA,. (2008) Expanding criteria for resectability of colorectal liver metastases. Oncologist 13: 51-64.
10. Shimada H, Tanaka K, Endou I, Ichikawa Y,. (2009) Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg 394: 973-983.
11. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H,. (2000) Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 232: 777-785.
12. Gallagher DJ, Kemeny N,. (2010) Metastatic colorectal cancer: from improved survival to potential cure. Oncology 78: 237-248.
13. Yang AD, Brouquet A, Vauthey JN,. (2010) Extending limits of resection for metastatic colorectal cancer: risk benefit ratio. J Surg Oncol 102: 996-1001.
14. Razafindratsira T, Isambert M, Evrard S,. (2011) Complications of intraoperative radiofrequency ablation of liver metastases. HPB 13: 15-23.
15. Evrard S, Rivoire M, Arnaud J, Lermite E, Bellera C, Fonck M, et al. (2012) Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection. Br J Surg 99: 558-565.
16. Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, et al. (2012) Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 23: 2619-2626.
17. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11: 38-47.
18. Lam VW, Spiro C, Laurence JM, Johnston E, Hollands MJ, Pleass HC, et al. (2012) A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 19: 1292-1301.
19. Strasberg SM,. (2005) Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 12: 351-355.
20. van de Poll MC, Siroen MP, van Leeuwen PA, Soeters PB, Melis GC, Boelens PG, et al. (2007) Interorgan amino acid exchange in humans: consequences for arginine and citrulline metabolism. Am J Clin Nutr 85: 167-172.
21. van Dam RM, Hendry PO, Coolsen MM, Bemelmans MH, Lassen K, Revhaug A, et al. (2008) Initial experience with a multimodal enhanced recovery programme in patients undergoing liver resection. Br J Surg 95: 969-975.
22. van den Broek MA, van Dam RM, van Breukelen GJ, Bemelmans MH, Oussoultzoglou E, Pessaux P, et al. (2011) Development of a composite endpoint for randomized controlled trials in liver surgery. Br J Surg 98: 1138-1145.
23. Marang-van de Mheen PJ, Stadlander MC, Kievit J,. (2006) Adverse outcomes in surgical patients: implementation of a nationwide reporting system. Qual Saf Health Care 15: 320-324.
24. Dindo D, Demartines N, Clavien PA,. (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240: 205-213.
25. de Haas RJ, Wicherts DA, Andreani P, Pascal G, Saliba F, Ichai P, et al. (2011) Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection. Ann Surg 253: 1069-1079.
26. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241: 715-722; discussion 722-724.
27. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, et al. (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250: 440-448.
28. Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. (2012) Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 4: 283-301.
29. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019.
30. van Iersel LB, Koopman M, van de Velde CJ, Mol L, van Persijn van Meerten EL, Hartgrink HH, et al. (2010) Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Ann Oncol 21: 1662-1667.
31. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. (2011) XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 105: 58-64.
32. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377: 2103-2114.
33. Wiering B, Oyen WJ, Adang EM, van der Sijp JR, Roumen RM, de Jong KP, et al. (2011) Long-term global quality of life in patients treated for colorectal liver metastases. Br J Surg 98: 565-571; discussion 571-572.
34. Langenhoff BS, Krabbe PF, Peerenboom L, Wobbes T, Ruers TJ,. (2006) Quality of life after surgical treatment of colorectal liver metastases. Br J Surg 93: 1007-1014.
35. Farges O, Goutte N, Bendersky N, Falissard B,. (2012) Incidence and risks of liver resection: an all-inclusive French nationwide study. Ann Surg 256: 697-704; discussion 704-705.
36. Schiesser M, Chen JW, Maddern GJ, Padbury RT,. (2008) Perioperative morbidity affects long-term survival in patients following liver resection for colorectal metastases. J Gastrointest Surg 12: 1054-1060.
37. Abbott AM, Parsons HM, Tuttle TM, Jensen EH,. (2013) Short-term outcomes after combined colon and liver resection for synchronous colon cancer liver metastases: a population study. Ann Surg Oncol 20: 139-147.
38. Vente MA, Wondergem M, van der Tweel I, van den Bosch MA, Zonnenberg BA, Lam MG, et al. (2009) Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 19: 951-959.
39. Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, et al. (2012) Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 255: 405-414.
40. Knoefel WT, Gabor I, Rehders A, Alexander A, Krausch M, Schulte am Esch J, et al. (2013) In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two-stage liver resection. Br J Surg 100: 388-394.
41. Neumann UP, Dejong CH,. (2013) Split decision. Br J Surg 100: 310-312.